Your Rh type is a label, either positive or negative, that describes whether your red blood cells carry a specific protein called the RhD protein on their surface. If the protein is present, you’re Rh-positive. If it’s absent, you’re Rh-negative. Combined with your ABO blood group (A, B, AB, or O), your Rh type completes your blood type. So when someone says they’re “O-positive” or “A-negative,” the positive or negative part is the Rh type.
What the RhD Protein Actually Does
The RhD protein sits embedded in the outer membrane of your red blood cells. It’s part of a larger complex of proteins that helps maintain the structural integrity of those cells. By connecting to the internal skeleton of the red blood cell, this protein complex keeps the cell flexible and durable enough to squeeze through tiny blood vessels without breaking apart. Beyond that structural role, the RhD protein is one of the most potent triggers of an immune response when introduced into someone who lacks it, which is why it matters so much in transfusions and pregnancy.
The Rh blood group system actually includes several related proteins beyond RhD, but the D protein is by far the most clinically important. When doctors refer to your “Rh type,” they’re almost always talking about whether you carry this one protein.
How Rh Type Is Inherited
Your Rh type is genetic. You inherit one copy of the relevant gene from each parent. Being Rh-positive is dominant, meaning you only need one copy of the RhD gene to produce the protein and test positive. Being Rh-negative requires inheriting two copies of a deleted or nonfunctional version of the gene, one from each parent.
This means two Rh-positive parents can have an Rh-negative child if both carry one silent copy of the deletion. A parent who is heterozygous (one working copy, one deleted copy) has a 50% chance of passing the deletion to each child. Only when a child inherits the deletion from both sides, becoming homozygous for it, will they be Rh-negative. In European populations, the most common cause of Rh-negative status is a complete deletion of the RhD gene, the result of an ancient genetic event where misaligned DNA segments crossed over during cell division.
How Common Is Rh-Negative Blood?
Rh-negative status varies dramatically by population. About 85% of people worldwide are Rh-positive, but the regional differences are striking. In East Asian countries like China, Japan, and Indonesia, fewer than 1% of the population is Rh-negative. In parts of Africa, the rate ranges from about 1% to 7%. Britain and the United States have higher rates, around 17% and 15% respectively.
The highest known concentration of Rh-negative individuals, roughly 29%, has been reported among Basque populations in Morocco and in parts of Saudi Arabia. These regional differences matter for blood banking: in countries where Rh-negative blood is rare, maintaining adequate supply for those who need it is a constant challenge.
Why Rh Type Matters for Blood Transfusions
If you’re Rh-negative and receive Rh-positive blood, your immune system may recognize the RhD protein as foreign and begin producing antibodies against it. This process, called alloimmunization, doesn’t always cause problems during the first exposure. But once those antibodies exist, any future transfusion with Rh-positive blood can trigger a hemolytic transfusion reaction, where your immune system attacks and destroys the donated red blood cells. This can range from mild to life-threatening.
For this reason, Rh-negative patients receive Rh-negative blood whenever possible. Rh-positive patients can safely receive either Rh-positive or Rh-negative blood, since their immune system already recognizes the RhD protein. Blood donors with any form of weak RhD expression are typed as Rh-positive to protect Rh-negative recipients from accidental exposure. Each transfusion carries some risk of sensitization to Rh-related proteins, so matching is taken seriously every time.
Rh Incompatibility in Pregnancy
The most well-known consequence of Rh type involves pregnancy. When an Rh-negative mother carries an Rh-positive baby, small amounts of fetal blood can cross the placenta and enter the mother’s bloodstream. Her immune system may treat those Rh-positive cells as invaders and produce anti-D antibodies in response.
This sensitization often causes no problems in a first pregnancy because the antibody response develops slowly. The real danger comes in subsequent pregnancies with another Rh-positive baby. The mother’s immune system, now primed, rapidly produces antibodies that cross back through the placenta and attack the baby’s red blood cells. This condition, called hemolytic disease of the fetus and newborn (HDFN), can cause severe anemia in the baby, jaundice within the first 24 hours after birth, and in the most serious cases, a dangerous buildup of fluid called hydrops fetalis.
Prenatal screening catches this risk early. Rh-negative pregnant women are tested for anti-D antibodies as part of routine care. If antibodies are detected, doctors monitor the pregnancy more closely, using ultrasound measurements of blood flow in the baby’s brain to detect fetal anemia.
How Rh Complications Are Prevented
The standard prevention for Rh sensitization during pregnancy is an injection of Rh immunoglobulin, a product that prevents the mother’s immune system from mounting a lasting response to fetal RhD-positive cells. The most common approach involves giving this injection around 28 weeks of pregnancy and again shortly after delivery if the baby is confirmed Rh-positive.
Different countries handle the dosing and timing slightly differently. Some guidelines recommend a single larger dose at 28 weeks, while others use two smaller doses at 28 and 34 weeks. The injection is also given after any event during pregnancy that could cause fetal blood to mix with the mother’s, such as an abdominal injury, amniocentesis, or miscarriage. This preventive approach has been remarkably effective. Before it was introduced, Rh-related HDFN was a leading cause of newborn illness and death. Today it’s largely preventable.
The Weak D Variant
Not everyone falls neatly into Rh-positive or Rh-negative. Roughly 0.2% to 1% of routine Rh typings produce an ambiguous result called a “serological weak D phenotype.” These individuals have the RhD protein on their red blood cells, but in reduced amounts or in a slightly altered form due to a variation in the gene.
How weak D is handled depends on context. Blood donors with weak D are classified as Rh-positive, since their blood could sensitize an Rh-negative recipient. But patients receiving transfusions and pregnant women with weak D are typically treated as Rh-negative as a safety precaution. For pregnant women, this means receiving Rh immunoglobulin even though they may not strictly need it. It’s an intentionally cautious approach: the small cost of an unnecessary injection is far preferable to the risk of sensitization if their particular variant turns out to be immunologically significant.
How Your Rh Type Is Determined
Rh typing is done with a simple blood test, often at the same time as ABO typing. A sample of your blood is mixed with a solution containing anti-D antibodies. If your red blood cells clump together, you have the RhD protein and are Rh-positive. If they don’t, you’re Rh-negative. The test takes minutes and is routinely performed during blood donation, before surgery, and at the first prenatal visit during pregnancy.
For people with ambiguous initial results, additional testing can determine whether they have a weak D variant. Genetic testing of the RHD gene itself can provide the most definitive answer in complex cases, identifying the exact type of variant and its clinical significance.